333 related articles for article (PubMed ID: 12451292)
1. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study.
Fraser AD; Worth D
Ther Drug Monit; 2002 Dec; 24(6):746-50. PubMed ID: 12451292
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2.
Fraser AD; Worth D
Forensic Sci Int; 2003 Apr; 133(1-2):26-31. PubMed ID: 12742686
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study.
Fraser AD; Worth D
Forensic Sci Int; 2003 Nov; 137(2-3):196-202. PubMed ID: 14609657
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.
Fraser AD; Worth D
Forensic Sci Int; 2004 Jul; 143(2-3):147-52. PubMed ID: 15240035
[TBL] [Abstract][Full Text] [Related]
5. Papain: a novel urine adulterant.
Burrows DL; Nicolaides A; Rice PJ; Dufforc M; Johnson DA; Ferslew KE
J Anal Toxicol; 2005; 29(5):275-95. PubMed ID: 16105251
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study.
Fraser AD; Worth D
J Anal Toxicol; 1999 Oct; 23(6):531-4. PubMed ID: 10517562
[TBL] [Abstract][Full Text] [Related]
7. Drug and chemical metabolites in clinical toxicology investigations: the importance of ethylene glycol, methanol and cannabinoid metabolite analyses.
Fraser AD; Coffin L; Worth D
Clin Biochem; 2002 Oct; 35(7):501-11. PubMed ID: 12493577
[TBL] [Abstract][Full Text] [Related]
8. Detection times of marijuana metabolites in urine by immunoassay and GC-MS.
Huestis MA; Mitchell JM; Cone EJ
J Anal Toxicol; 1995 Oct; 19(6):443-9. PubMed ID: 8926739
[TBL] [Abstract][Full Text] [Related]
9. Investigation of nitrite adulteration on the immunoassay and GC-MS analysis of cannabinoids in urine specimens.
Tsai LS; ElSohly MA; Tsai SF; Murphy TP; Twarowska B; Salamone SJ
J Anal Toxicol; 2000; 24(8):708-14. PubMed ID: 11110026
[TBL] [Abstract][Full Text] [Related]
10. Determination of the Cross-Reactivity of the Biological Metabolite (-)-trans-Δ9-Tetrahydrocannabinol-Carboxylic Acid-Glucuronide (THC-COOH-Gluc) for Cannabinoid Immunoassays.
Grafinger KE; Weinmann W
J Anal Toxicol; 2021 Mar; 45(3):291-296. PubMed ID: 32518954
[TBL] [Abstract][Full Text] [Related]
11. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana.
Niedbala RS; Kardos KW; Fritch DF; Kardos S; Fries T; Waga J; Robb J; Cone EJ
J Anal Toxicol; 2001; 25(5):289-303. PubMed ID: 11499881
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Delta-9-Tetrahydrocannabinol Carboxylic Acid (Δ9-THC-COOH) Immunoassay and a Gas Chromatography-Mass Spectrometry (GC-MS) Method for the Detection of Delta-8-Tetrahydrocannabinol Carboxylic Acid (Δ8-THC-COOH).
Baird SN; Frazee CC; Garg U
J Appl Lab Med; 2023 Jul; 8(4):665-673. PubMed ID: 37071885
[TBL] [Abstract][Full Text] [Related]
13. Performance of Abusign drugs-of-abuse slide tests with particluar emphasis on concentrations near the cutoff: comparison with FPIA-ADx and confirmation of results with GC-MS.
Ros JJ; Pelders MG; Egberts AC
J Anal Toxicol; 1998; 22(1):40-4. PubMed ID: 9491967
[TBL] [Abstract][Full Text] [Related]
14. Detection of the marijuana metabolite 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens and its contribution to positive results in screening assays.
Moore C; Ross W; Coulter C; Adams L; Rana S; Vincent M; Soares J
J Anal Toxicol; 2006 Sep; 30(7):413-8. PubMed ID: 16959132
[TBL] [Abstract][Full Text] [Related]
15. A comparison of ONTRAK TESTCUP, abuscreen ONTRAK, abuscreen ONLINE, and GC/MS urinalysis test results.
Crouch DJ; Cheever ML; Andrenyak DM; Kuntz DJ; Loughmiller DL
J Forensic Sci; 1998 Jan; 43(1):35-40. PubMed ID: 9456522
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
Fraser AD; Meatherall R
J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
[TBL] [Abstract][Full Text] [Related]
17. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
ElSohly MA; deWit H; Wachtel SR; Feng S; Murphy TP
J Anal Toxicol; 2001 Oct; 25(7):565-71. PubMed ID: 11599601
[TBL] [Abstract][Full Text] [Related]
18. A comparison of Roche Kinetic Interaction of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS analysis for 11-nor-9-carboxy-delta9-tetrahydrocannabinol.
Lyons TP; Okano CK; Kuhnle JA; Bruins MR; Darwin WD; Moolchan ET; Huestis MA
J Anal Toxicol; 2001 Oct; 25(7):559-64. PubMed ID: 11599600
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users.
Smith-Kielland A; Skuterud B; Mørland J
J Anal Toxicol; 1999 Sep; 23(5):323-32. PubMed ID: 10488918
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fluorescence polarization immunoassay, enzyme immunoassay, and thin-layer chromatography for urine cannabinoid screening. Effects of analyte adsorption and vigorous mixing of specimen on detectability.
Dextraze P; Griffiths WC; Camara P; Audette L; Rosner M
Ann Clin Lab Sci; 1989; 19(2):133-8. PubMed ID: 2546480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
